Why is Kiniksa Pharmaceuticals International Plc ?
- OPERATING CASH FLOW(Y) Highest at USD 66.94 MM
- DEBT-EQUITY RATIO (HY) Lowest at -60.2 %
- NET SALES(Q) Highest at USD 156.8 MM
- Over the past year, while the stock has generated a return of 111.36%, its profits have fallen by 0%
- Along with generating 111.36% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
How much should you buy?
- Overall Portfolio exposure to Kiniksa Pharmaceuticals International Plc should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at USD 66.94 MM
Lowest at -60.2 %
Highest at USD 156.8 MM
Highest at USD 576.12 MM
Highest at 20.22 times
Highest at USD 20.52 MM
Highest at 13.09 %
Highest at USD 22.88 MM
Highest at USD 17.83 MM
Highest at USD 0.23
Grown by 10.38% (YoY
Here's what is working for Kiniksa Pharmaceuticals International Plc
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
Net Sales (USD MM)
Debt-Equity Ratio
Operating Cash Flows (USD MM)
Net Sales (USD MM)
Operating Profit (USD MM)
Operating Profit to Sales
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
EPS (USD)
Cash and Cash Equivalents
Debtors Turnover Ratio
Here's what is not working for Kiniksa Pharmaceuticals International Plc
Raw Material Cost as a percentage of Sales






